MedTrace Logo

NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers (BE)

NCT05354713 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2023-05-06

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetics of NVP-1805 and coadministration of NVP-1805-R1 with NVP-1805-R2

Conditions

  • Healthy Volunteers

Interventions

DRUG

NVP-1805

NVP-1805 (80/10/20.8mg)

DRUG

NVP-1805-R1 and NVP-1805-R2

coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)

Sponsors & Collaborators

  • NVP Healthcare

    lead INDUSTRY

Principal Investigators

  • Jaewoo Kim · H Plus Yangji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-05
Primary Completion
2023-03-20
Completion
2023-04-27

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05354713 on ClinicalTrials.gov